The once high-flying Danish drugmaker has struggled to fend off rivals in the weight-loss industry, especially Eli Lilly, ...

By Maggie Fick LONDON, Feb 5 (Reuters) - Novo Nordisk CEO Mike Doustdar was in a meeting with investors on Thursday ...

Hims said it would sell a copy of the newly launched weight loss pill for $49, far less than the $149 Novo sells the branded pill for.

Hims & Hers is making available a cheaper, compounded version of the Wegovy weight loss pill sold by Novo Nordisk, prompting the drugmaker to accuse the telehealth platform of “illegal mass ...

Telehealth company Hims & Hers is launching a cheaper, off-brand version of the blockbuster weight loss pill Wegovy ...

Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to ...

Q4 2025 Earnings Call February 5, 2026 8:15 AM ESTCompany ParticipantsMaziar Doustdar - President, CEO & Member of ...

Shortly after reporting weaker-than-expected sales of its injectable GLP-1 drugs, Novo Nordisk revealed clinical results with an oral alternative that suggest it can offer comparable efficacy with ...

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) shares climbed about 4% on Friday, touching levels last seen in October, after early U.S. prescription data for its Wegovy weight-loss ...

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, ...

Novo Nordisk (NVO) said on Thursday that it will take legal and regulatory steps in response to plans by Hims & Hers Health ...

Eli Lilly leads the weight loss market ahead of Novo Nordisk. Eli Lilly also has a more diversified lineup of products than its peer. Even considering its seemingly more reasonable valuation, Novo ...